cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
Published 1 year ago • 185 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:21
captivate: ibrutinib and venetoclax in cll
-
4:52
apoptosis and venetoclax
-
8:14
progress in the treatment of tp53 mutated aml
-
2:13
venetoclax rituximab for r/r cll: 7-year results of the murano trial
-
1:11
cll2-give trial: investigating chemotherapy-free treatment of cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:38
the importance of tp53 in cll
-
1:56
emerging ibrutinib-based combinations in cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
1:00
reveng: venetoclax and obinutuzumab in cll
-
2:20
car-t therapy as a replacement for triple combination therapy in cll
-
1:12
patients with cll on continuous ibrutinib have a life expectancy comparable to healthy individuals
-
2:00
ibrutinib: use in small cll subgroups only?
-
2:36
changing epigenetic markers in cll patients on ibrutinib
-
0:58
ibrutinib for cll within a population-based setting: a promising outlook